Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bimagrumab · LY3985863, BYM-338

Monoclonal antibody · Antagonist of Type II activin receptor (ActRII/ACVR2) (ACVR2A) · developed by ELI LILLY &

Phase 2 Most advanced trial (none active)
LLY Developer
1 Registered trials

What is Bimagrumab?

Bimagrumab is a human monoclonal antibody that binds type II activin receptors (ActRII), blocking the binding of myostatin and activin and the signaling that follows. It is being studied in obesity and overweight.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LY3985863, BYM-338, VER201
Drug type
Monoclonal antibody
Targets
Type II activin receptor (ActRII/ACVR2) (ACVR2A)
Mechanism
Antagonist of Type II activin receptor (ActRII/ACVR2) (ACVR2A)
Pathways
ActRII-mediated signaling, protein synthesis, protein degradation, skeletal muscle cell growth
Therapy area
Metabolic
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
N15SW1DIV8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06643728 Phase 2 Obesity Completed LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ObesityOverweight

More from ELI LILLY &

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Bimagrumab

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.